TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) announces that it has granted its directors, officers and employees options to purchase a total of 6,751,000 common shares of Antibe pursuant to the Corporation’s stock option plan. Each option has an exercise price of $0.145, being the closing price of Antibe shares on March 8, 2016, and an expiry date of March 9, 2026. Twenty-five percent of the granted options vest on the grant date and 1/36th of the remaining options vest in each of the subsequent 36 months.
